Participated · Series B · Oct 2022

Alto Neuroscience is a Mountain View, CA–based clinical-stage biopharmaceutical company focused on precision psychiatry therapies that pair digital biomarkers with novel CNS drugs. Its lead candidate, ALTO-207—a fixed-dose combination of pramipexole and ondansetron—hit primary and secondary endpoints in a 32-patient Phase 2a study for treatment-resistant depression and is slated to enter Phase 2b by mid-2026 and Phase 3 in early 2027. The firm also advances ALTO-101, which recently secured FDA Fast Track status for cognitive impairment associated with schizophrenia. Alto’s platform employs electroencephalography and cognitive testing to tailor treatments to individual patients. The company carries a market capitalization of about $164.6 million and reports a strong liquidity profile, with a current ratio of 18.43 and more cash than debt, though it is experiencing rapid cash burn. The newly raised capital should extend its runway and fund upcoming clinical milestones.

Participated · Series C · Nov 2021

Peek is a San Francisco–based technology company offering a comprehensive operating system for the experiences industry, spanning museums, theme parks, cultural attractions, tours, and activities. Its cloud platform supports ticketing, memberships, donations, RFID-enabled access control, and other guest-management tools designed to boost merchant revenues, save staff time, and improve visitor journeys. To date the company has processed more than $7 billion in bookings through its software. Peek’s customer roster includes marquee institutions such as MoMA, the Whitney Museum, Seattle Aquarium, Bryant Park, Looping Group, and the Museum of Ice Cream. In 2025 the company expanded its capabilities and market reach to over 150 million consumers by acquiring ACME Ticketing, which specializes in cultural-institution ticketing and membership infrastructure, and Connect&GO, which provides RFID attraction-management technology for complex venues. These additions deepened Peek’s domain expertise in both back-office and on-site visitor operations. The newly raised capital will fund further product development and operational scale.

Participated · Series C · Oct 2021

Cambrian Biopharma is a New York-based longevity biotech advancing multiple assets that each target a biological driver of aging. Led by CEO James Peyer and co‑founder and chairman Christian Angermayer, the company develops therapeutics intended to treat specific age-related diseases first and then be deployed as preventative medicines to lengthen healthspan and improve quality of life. Cambrian operates as a Distributed Development Company (DisCo) with a sourcing and development engine that enables identification of science, deep due diligence, deployment of capital and teams of drug development experts under the same model. It has 14 novel therapeutics in development across its majority-held pipeline companies. The company intends to use new funds to develop therapeutics to combat biological drivers of aging, treat and prevent age-related diseases and lengthen healthspan. With the Series C, Cambrian has raised approximately $160 million since its founding in 2019.

Participated · Series A · Sep 2021

Delix Therapeutics develops small‑molecule psychoplastogens that rapidly induce structural and functional neural changes in targeted brain areas. Its compounds are inspired by psychedelic compounds but are engineered to preserve efficacy while avoiding hallucinogenic properties and other safety liabilities. The company is advancing multiple candidates through preclinical and clinical development with the goal of bringing FDA‑approved, take‑home medicines to patients. Delix intends to use new funds to grow its drug development program, expand its pipeline and platform, hire additional team members, and pursue strategic opportunities in 2022. The company is led by CEO Mark Rus and is based in Boston, MA. Financially, Delix recently completed a convertible note financing and secured a strategic credit facility to support its programs alongside a prior $70M Series A in September 2021. Delix Therapeutics is a Boston-based preclinical neuroscience company developing non-hallucinatory, neuroplasticity-promoting therapeutics called psychoplastogens to treat mental illness and other brain disorders at scale. Its small-molecule compounds are designed to rapidly induce structural and functional neural changes in targeted brain regions while avoiding the hallucinogenic effects of first-generation psychedelics. Delix's discovery engine has produced nearly 1,000 novel compounds and identified several potential clinical development candidates. Its most advanced, orally bioavailable analogs—profiled in Nature and Cell—seek to preserve long-lasting beneficial neural rewiring without the safety liabilities and access barriers of classic psychedelics. The company raised $70M in a Series A to advance its non-hallucinatory, take-home candidates into clinical trials and to expand its team. DLX-1 and DLX-7, the first two development candidates, are undergoing pre-IND safety and toxicology studies to enable clinical trials in 2022.

Participated · Seed · Sep 2021

Upmin offers a digital platform that automates and accelerates professional property-management processes, providing owners and landlords a transparent customer account to view data, activities and progress. The service includes an all-round management package and an optional rental package covering marketing, viewings, tenant search, acceptance and handover. The company relies on state-of-the-art technology to reduce manual work, save time and lower costs for property owners. After one year of operations Upmin is already managing more than 1,000 units across Germany. The start-up plans to use new funding to expand services, pursue strategic acquisitions and hire roughly 25 additional employees across development, sales and administration. Founder and CEO Henning Frank brings about 15 years of startup and real-estate experience, including prior CEO and managing-director roles, which the company cites as central to its growth plans.